Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies
Open Access
- 3 November 2020
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 11 (44) , 4016-4027
Abstract
Https://doi.org/10.18632/oncotarget.27790 Michael E. Clark, Helen Rizos, Michelle R. Pereira, Ashleigh C. McEvoy, Gabriela Marsavela, Leslie Calapre, Katie Meehan, Olivia Ruhen, Muhammad A. Khattak,...Keywords
This publication has 61 references indexed in Scilit:
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Telomere-Specific Reverse Transcriptase (hTERT) and Cell-free RNA in Plasma as Predictors of Pathologic Tumor Response in Rectal Cancer Patients Receiving Neoadjuvant ChemoradiotherapyAnnals of Surgical Oncology, 2012
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- The eight human “canonical” ribonucleases: Molecular diversity, catalytic properties, and special biological actions of the enzyme proteinsFEBS Letters, 2010
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate CancerCancer Research, 2008
- Cell‐free DNA and RNA in Plasma as a New Molecular Marker for Prostate and Breast CancerAnnals of the New York Academy of Sciences, 2006
- Characterization of Amplifiable, Circulating RNA in Plasma and Its Potential as a Tool for Cancer DiagnosticsClinical Chemistry, 2004
- Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cellsGut, 2002
- Circulating RNA as a Tumor MarkerAnnals of the New York Academy of Sciences, 2001